Step it Up: An Exercise and Behaviour Change Programme for People With Multiple Sclerosis
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02301442 |
Recruitment Status :
Completed
First Posted : November 26, 2014
Last Update Posted : May 13, 2016
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Multiple Sclerosis | Behavioral: Exercise + behaviour change intervention Behavioral: Exercise + control education | Not Applicable |

Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 65 participants |
Allocation: | Randomized |
Intervention Model: | Single Group Assignment |
Masking: | Double (Participant, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | A Randomised Controlled Trial of an Exercise Plus Behaviour Change Intervention in People With MS: the "Step it Up" Study Protocol |
Study Start Date : | September 2014 |
Actual Primary Completion Date : | February 2016 |
Actual Study Completion Date : | February 2016 |

Arm | Intervention/treatment |
---|---|
Experimental: Exercise + behaviour change intervention
This arm of the trial includes assessments at weeks 0, 12, 24 and 36. A 10-week exercise + behaviour change intervention will be delivered by physiotherapists between weeks 1 and 11.
|
Behavioral: Exercise + behaviour change intervention
In addition to the same exercise intervention as the control group, this group will receive a behaviour change intervention. This will be delivered after each exercise session and will incorporate the elements: self-efficacy, outcome expectations, impediments and goal-setting. On the weeks when the participants do not attend group sessions, they will receive telephone calls from physiotherapists. This will consist of guided conversations that consider content delivered in previous sessions. |
Active Comparator: Exercise + control education
This arm of the trial includes assessments at weeks 0, 12, 24 and 36. A 10-week exercise + control education intervention will be delivered by physiotherapists between weeks 1 and 11.
|
Behavioral: Exercise + control education
The control group will receive exercise and education components. The exercise intervention includes aerobic & strengthening components and are in line with MS exercise guidelines (Latimer-Cheung et al 2013). The aerobic activity is walking, measured using pedometers & exercise logs. The strengthening programme consists of 10 exercises targeting major muscle groups for the upper and lower extremities using elastic resistance band. Over the 10-week programme participants will attend 6 group exercise class, supplemented with telephone calls in the weeks without classes. After each group exercise class this group will receive an education session about the following: diet, vitamin D, sleep, temperature and hydration, and immunisations and vaccinations. |
- Change in walking mobility from weeks 1 to 36 [ Time Frame: Weeks 1 to 36 ]Change in walking mobility will be measured using the Timed up and Go test, the Six Minute Walk Test and the Multiple Sclerosis Walking Scale-12. These measures will be completed at weeks 1, 12, 24 and 36. The primary outcome will be the change over time from week 1 to week 36.
- Change in lower limb functional muscle strength from weeks 1 to 36 [ Time Frame: Weeks 1 to 36 ]Change in lower limb muscle strength will be measured using the 5 times sit to stand test. This measure will be completed at weeks 1, 12, 24 and 36.
- Change in aerobic fitness from weeks 1 to 36 [ Time Frame: Weeks 1 to 36 ]Change in aerobic fitness will be measured using the Modified Canadian Aerobic Fitness Test. This measure will be completed at weeks 1, 12, 24 and 36.
- Change in anxiety and depression from weeks 1 to 36 [ Time Frame: Weeks 1 to 36 ]Change in anxiety and depression will be measured using the Hospital Anxiety and Depression Scale. This measure will be completed at weeks 1, 12, 24 and 36.
- Change in cognitive processing from weeks 1 to 36 [ Time Frame: Weeks 1 to 36 ]Change in cognitive processing will be measured using the Symbol Digit Modalities Test. This measure will be completed at weeks 1, 12, 24 and 36.
- Change in physical activity levels from weeks 1 to 36 [ Time Frame: Weeks 1 to 36 ]Change in phyiscal activity levels will be measured using the Godin Leisure-Time Exercise Questionnaire, the International Physical Activity Questionnaire and an objective measure of physical activity- the SenseWear Arm band accelerometer. These measures will be completed at weeks 1, 12, 24 and 36.
- Change in self-reported fatigue from weeks 1 to 36 [ Time Frame: Weeks 1 to 36 ]Change in self-reported fatigue will be measured using the Modified Fatigue Impact Scale. This measure will be completed at weeks 1, 12, 24 and 36.
- Change in self-reported impact of MS from weeks 1 to 36 [ Time Frame: Weeks 1 to 36 ]Change in self-reported impact of MS will be measured using the Multiple Sclerosis Impact Scale-29. This measure will be completed at weeks 1, 12, 24 and 36.
- Adherence to the intervention [ Time Frame: Week 12 ]Participants adherence to the intervention will be measured at week 12 (post-intervention) using self-report (participant-reported) exercise logs and adherence logs recorded by the trial interventionalists.
- Change in Social Cognitive Theory domains from weeks 1 to 36 [ Time Frame: Weeks 1 to 36 ]Change in Social Cognitive Theory domains will be measured using the Exercise Self-Efficacy Scale, the Exercise Goal Setting scale, the Multidimensional Outcomes Expectations for Exercise Scale and the Social Provisions Scale. These measures will be completed at weeks 1, 12, 24 and 36.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Physician-confirmed formal diagnosis of MS
- Patient Determined Disease Steps score of 0-3
- A sedentary lifestyle (< 30 minutes of moderate to strenuous exercise one day or more per week over the last six months)
- Willing to give written informed consent.
Exclusion Criteria:
- Pregnancy
- MS relapse in the last 12 weeks
- Changes to MS medication or steroid treatment in the last 12 weeks.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02301442
Ireland | |
Department of Clinical Therapies, University of Limerick | |
Limerick, Munster, Ireland |
Principal Investigator: | Susan Coote, PhD | University of Limerick |
Responsible Party: | University of Limerick |
ClinicalTrials.gov Identifier: | NCT02301442 |
Other Study ID Numbers: |
ULimerick |
First Posted: | November 26, 2014 Key Record Dates |
Last Update Posted: | May 13, 2016 |
Last Verified: | May 2016 |
Multiple Sclerosis Sclerosis Pathologic Processes Demyelinating Autoimmune Diseases, CNS Autoimmune Diseases of the Nervous System |
Nervous System Diseases Demyelinating Diseases Autoimmune Diseases Immune System Diseases |